Protalix BioTherapeutics (PLX) Interest Coverage Ratio (QoQ) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -492.90% |
| Dec 31, 2024 | 1,045.47% |
| Sep 30, 2024 | 339.71% |
| Jun 30, 2024 | 48.57% |
| Mar 31, 2024 | -71.63% |
| Dec 31, 2023 | -76.85% |
| Sep 30, 2023 | -126.21% |
| Jun 30, 2023 | 513.00% |
| Mar 31, 2023 | -132.85% |
| Dec 31, 2022 | 335.81% |
| Sep 30, 2022 | 44.85% |
| Jun 30, 2022 | -193.03% |
| Mar 31, 2022 | 51.85% |
| Dec 31, 2021 | -703.44% |
| Sep 30, 2021 | 81.20% |
| Jun 30, 2021 | -142.12% |
| Mar 31, 2021 | -252.60% |
| Dec 31, 2020 | 186.05% |
| Sep 30, 2020 | -13.81% |
| Jun 30, 2020 | -179.12% |
| Mar 31, 2020 | 38.01% |
| Dec 31, 2019 | 239.83% |
| Sep 30, 2019 | 75.40% |
| Jun 30, 2019 | -6.23% |
| Mar 31, 2019 | -46.08% |
| Dec 31, 2018 | 4.48% |
| Sep 30, 2018 | 45.08% |
| Jun 30, 2018 | -62.11% |
| Mar 31, 2018 | 77.82% |
| Dec 31, 2017 | -395.75% |
| Sep 30, 2017 | 40.54% |
| Jun 30, 2017 | -16.35% |
| Mar 31, 2017 | 48.34% |
| Dec 31, 2016 | 19.19% |
| Sep 30, 2016 | 33.72% |
| Jun 30, 2016 | -26.70% |
| Mar 31, 2016 | -5.07% |
| Dec 31, 2015 | -70.49% |
| Sep 30, 2015 | 44.17% |
| Jun 30, 2015 | -86.91% |